1-[(2S,4aR,6R,7R,7aR)-7-chloro-7-methyl-2-oxo-2-propan-2-yloxy-4,4a,6,7a-tetrahydrofuro[3,2-d][1,3,2]dioxaphosphinin-6-yl]pyrimidine-2,4-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-[(2S,4aR,6R,7R,7aR)-7-chloro-7-methyl-2-oxo-2-propan-2-yloxy-4,4a,6,7a-tetrahydrofuro[3,2-d][1,3,2]dioxaphosphinin-6-yl]pyrimidine-2,4-dione
• 化学式: C₁₃H₁₈ClN₂O₇P
• 分子量: 380.72
• InChiKey: NXMUNKWRQMIFFC-CWFQDHPOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• [EN] PRODUCTION OF CYCLIC PHOSPHATE, PHOSPHORAMIDATE, THIOPHOSPHATE, AND PHOSPHONATE NUCLEOSIDE COMPOUNDS<br/>[FR] PRODUCTION DE COMPOSÉS CYCLIQUES DE TYPE PHOSPHATE, PHOSPHORAMIDATE, THIOPHOSPHATE, ET PHOSPHONATE NUCLÉOSIDIQUE
  申请人：IDENIX PHARMACEUTICALS INC

  公开号：WO2015095305A1

  公开（公告）日：2015-06-25

  Provided herein are methods for the production of cyclic phosphate, cyclic phosphoramidate, cyclic thiophosphate, and cyclic phosphonate nucleoside compounds. Also provided herein are compounds useful in the production of cyclic phosphate, cyclic phosphoramidate, cyclic thiophosphate, and cyclic phosphonate nucleoside compounds. In certain embodiments, the cyclic phosphate, cyclic phosphoramidate, cyclic thiophosphate, and cyclic phosphonate nucleoside compounds are of Formula (I): wherein: Base, RA, RB, X, R1 and R2 are as defined herein. The cyclic phosphate, cyclic phosphoramidate, cyclic thiophosphate, and cyclic phosphonate nucleoside compounds are useful in the treatment of viral infections, including hepatitis C virus infections in hosts in need thereof.

  本文提供了一种生产环磷酸酯、环磷酰胺酸酯、环硫代磷酸酯和环膦酸酯核苷化合物的方法。本文还提供了在生产环磷酸酯、环磷酰胺酸酯、环硫代磷酸酯和环膦酸酯核苷化合物中有用的化合物。在某些实施例中，环磷酸酯、环磷酰胺酸酯、环硫代磷酸酯和环膦酸酯核苷化合物的化学式为(I)：其中：Base、RA、RB、X、R1和R2如本文所定义。环磷酸酯、环磷酰胺酸酯、环硫代磷酸酯和环膦酸酯核苷化合物在治疗病毒感染方面具有用途，包括治疗需要的宿主体内的丙型肝炎病毒感染。
• 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION
  申请人：Idenix Pharmaceuticals, Inc.

  公开号：US20160083413A1

  公开（公告）日：2016-03-24

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2′-chloro nucleosides according to Formula 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.

  本文提供了用于治疗黄病毒科感染，包括丙型肝炎(HCV)感染的化合物、组合物和方法。在某些实施例中，公开了核苷衍生物的化合物和组合物，可以单独或与其他抗病毒药物联合使用。在某些实施例中，化合物是根据公式2001的2'-氯核苷，或其药学上可接受的盐、溶剂化合物、立体异构体形式、互变异构体形式或多态形式，其中B、Z和PD如本文所述。